It has been reported that the transcriptional factor STAT5 serves as a direct negative regulator of BCL6 in lymphomas (Walker et al., 2007), and FoxO3a promoted BCL6 expression in leukemia cells exposed to BCR-ABL inhibitors (Duy et al., 2011; Fernández de Mattos et al., 2004). Here, ABL1 is linked to lymphoma.